About us

Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.

We are the leaders in exploring the hidden depths of cancer and T-cell biology to discover and characterize Dark Antigens™, a novel class of shared immunotherapy targets that arise from altered cellular processes in cancer cells. We believe that Dark Antigens have the core attributes that will enable cancer immunotherapies to improve treatment outcomes for broad patient populations.

Enara Bio is backed by prominent life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with world-leading companies and academic institutions, such as Boehringer Ingelheim and the Francis Crick Institute, to help drive our differentiated science-led approach.

Enara Bio Our Story Poster

The Team

Andrew Fadden
Vice President, Corporate Development
Kevin Pojasek
President and Chief Executive Officer
David Watson
Chief Operating Officer
Sophie Papa
Chief Medical Officer
Joseph Dukes
Vice President, Head of Research
David Watson (Chief Operating Officer), Andrew Fadden (Vice President, Corporate Development), Kevin Pojasek (President and Chief Executive Officer), Joe Dukes (Vice President, Head of Research), Sophie Papa (Chief Medical Officer)
Charlotte Howard (Associate Director, Corporate and Executive Administration)
Kate Fynes (Cell Process Development Lead, Principal Scientist), Assa Oumie (Principal Scientist), Selsabil Dhaouadi (Scientist)
Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist)
Emily Lam (Senior Scientist), Duncan Howie (Director of Immunology), Suzanne Cole (Principal Scientist),
Luke Williams (Senior Director, Biology)
Beth Turner (Head of Product and Pipeline Project Management), Simon Jarvis (IT Director), Kate Nicholson (Head of Business Operations), Jonathon Dines (Finance Director), Ray Duffy (Associate Director, Facilities and EHS)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development), Jonathan Porter (Director, Intellectual Property)
Rayner Queiroz (Senior Scientist), Fabio Marino (Associate Director, Immunopeptidomics), Rose Gathungu (Principal Scientist)
Duncan Howie (Director, Immunology)
Sophie Papa (Chief Medical Officer), Joseph Dukes (Vice President, Head of Research)
Eleanor Denham (Scientist), Phyllis Tea (Research Associate)
Jon Silk (Director, MR1 Research)
Jo Senra (Associate Director, Preclinical Validation), Veronica Freire-Beneitez (Senior Scientist), Vicki Jefferson (Scientist), Emily Tye (Research Associate)
Adam Taylor (Senior Director, Business Insights and Strategy), Andrew Fadden (Vice President, Corporate Development)
Ron Wolchinsky (Associate Director, Molecular Immunology)
Emily Lam (Senior Scientist), Suzanne Cole (Principal Scientist), Phyllis Tea (Research Associate), Terri Cornforth (Principal Scientist), Eleanor Denham (Scientist), Duncan Howie (Director of Immunology)

Board of Directors

Scientific Advisory Board

Charles Dunn

Board Observer

Charles is a Vice President in the SV biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage opportunities. Charles serves as a board observer at Autifony Therapeutics, EnaraBio, Pulmocide, Imbria Therapeutics, and Mestag Therapeutics which he also helped incubate and launch. Charles identifies and evaluates new opportunities and advises portfolio company management on strategy, fundraising, and business development. Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.